2026-06-25T10:25:43-05:00 2025-12-31 260794367 UHY ADVISORS MID-ATLANTIC INC 8601 ROBERT FULTON DRIVE SUITE 210 COLUMBIA MD 21046 990 2025-01-01 521336903 APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION INC APLA 3012797202 401 N WASHINGTON ST 430 ROCKVILLE MD 20850 BRAD A WONG CEO AND EXECUTIVE DIRECTOR 3012797202 2026-04-22 1 HSUANYI WANG P03292356 4107205220 2026-04-22 2025 2025-03-06 01:10:19Z BRAD A WONG 401 N WASHINGTON ST 430 ROCKVILLE MD 20850 3281273 0 X WWW.AAMDS.ORG X 1983 MD (SEE SCHEDULE O)TO SUPPORT PATIENTS, FAMILIES AND CAREGIVERS COPING WITH APLASTIC ANEMIA, MDS, PNH AND RELATED BONE MARROW FAILURE DISEASES BY PROVIDING ANSWERS, SUPPORT AND HOPE. 15 15 10 150 0 0 2904654 3037843 0 0 223442 180015 -88223 -47416 3039873 3170442 174479 215388 0 0 1329172 1430475 0 0 338138 1454020 1277523 2957671 2923386 82202 247056 7464678 8296083 747119 713867 6717559 7582216 TO SUPPORT PATIENTS, FAMILIES AND CAREGIVERS COPING WITH APLASTIC ANEMIA, MDS, PNH AND RELATED BONE MARROW FAILURE DISEASES BY PROVIDING ANSWERS, SUPPORT AND HOPE. 0 0 2304676 215388 PROVIDE PATIENT EDUCATION, ASSISTANCE, ADVOCACY, AND SUPPORT, TO CREATE AND DISTRIBUTE EDUCATIONAL MATERIALS AND MEDICAL INFORMATION, AND TO SUPPORT RESEARCH TO FIND TREATMENT FOR VARIOUS BONE MARROW DISEASES, INCLUDING APLASTIC ANEMIA (AA), MYELODYSPLASTIC SYNDROMES (MDS), PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), AND RELATED BONE MARROW FAILURE DISEASES. 2304676 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 22 0 1 10 1 0 0 0 0 0 0 0 0 0 0 0 0 X 15 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 CA IL MD MI NJ NY PA VA X X MICHELLE HALL 3012797202 401 N WASHINGTON ST SUITE 430 ROCKVILLE MD 20850 DEBORAH COOK CHAIR 2.00 X X 0 0 0 JUDY PAULETTE VICE-CHAIR 1.00 X X 0 0 0 CHRIS MILLS SECRETARY 1.00 X X 0 0 0 PETER MILLER TREASURER 1.00 X X 0 0 0 MARLENA CONNOR DIRECTOR 1.00 X 0 0 0 BART S FISHER DIRECTOR 1.00 X 0 0 0 JAMES GAJEWSKI MD DIRECTOR 1.00 X 0 0 0 TRAVIS GEORGIEFF DIRECTOR 1.00 X 0 0 0 STEPHANIE HAMM DIRECTOR 1.00 X 0 0 0 MARY HOROWITZ MD DIRECTOR 1.00 X 0 0 0 ABE KADER DIRECTOR 1.00 X 0 0 0 MELANIE MARQUEZ DIRECTOR 1.00 X 0 0 0 REBECCA DOANE DIRECTOR 1.00 X 0 0 0 ERIE SAMPSON DIRECTOR 1.00 X 0 0 0 HETAL SONI DIRECTOR 1.00 X 0 0 0 BRAD A WONG CEO & EXECUTIVE DIRECTOR 40.00 X 278193 0 35984 AZALEA CANDELARIA SR. DIRECTOR OF DEVELOPMENT 40.00 X 181537 0 8473 ALICE HOUK SR. DIR. OF PATIENT & PROF'L PROGRAMS 40.00 X 151779 0 20412 LEIGH A CLARK DIRECTOR OF PATIENT PROGRAMS 40.00 X 113490 0 11700 ALISON SENEY DIRECTOR OF DEVELOPMENT 40.00 X 105549 0 11100 830548 0 87669 5 0 1 0 CALIBRE CPA GROUP PLLC 7501 WISCONSIN AVENUE SUITE 1200 WE BETHESDA MD 20814 PROFESSIONAL SERVICES 200713 1 480617 134856 2422370 15538 3037843 180018 180018 47346 47349 -3 -3 -3 16066 480617 63482 -47416 -47416 3170442 0 0 132599 X 120000 120000 5388 5388 90000 90000 314177 235633 47127 31417 942996 683506 56592 202898 18685 13413 657 4615 71817 52004 4129 15684 82800 60491 6666 15643 1455 1070 385 189207 139141 50066 29069 29069 416457 401892 8063 6502 75117 42318 5905 26894 103663 69582 22645 11436 106913 69722 25088 12103 234337 231560 2777 56356 36752 13224 6380 14707 9591 3451 1665 AWARDS, GRANTS AND HONO 30091 29471 620 BANK SERVICE FEES 20095 13105 4715 2275 PROFESSIONAL DEVELOPMEN 56 37 13 6 2923386 2304676 280572 338138 380494 268867 1180024 1715561 722213 186785 19842 20042 486919 227976 235035 258943 4157306 5099267 769764 746618 7464678 8296083 166702 197275 580417 516592 747119 713867 X 5302941 6678556 1414618 903660 6717559 7582216 7464678 8296083 247056 617601 0 X X 0 1 X 1 0 X 3388728 3184514 3336920 2904654 3037843 15852659 3388728 3184514 3336920 2904654 3037843 15852659 6785412 9067247 51744 48543 126602 194047 180018 600954 16453613 0.55110 0.57290 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 486919 227976 258943 258943 SECURITY DEPOSITS 8285 CHARITABLE REMAINDER TRUST 289199 RIGHT-OF-USE ASSET - FINANCE, NET 18038 RIGHT-OF-USE ASSET - OPERATING, NET 431096 746618 LEASE LIABILITY - FINANCE 18038 LEASE LIABILITY - OPERATING 498554 516592 X 3831406 617601 8950 63482 690033 3141373 29069 29069 3170442 2966749 8950 63482 72432 2894317 29069 29069 2923386 PART X, LINE 2: FOR THE YEAR ENDED DECEMBER 31, 2025, THE FOUNDATION HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES AND HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: DIRECT EXPENSE FROM FUNDRAISING EVENTS REPORTED ON PART VIII LINE 8B 63,482. PART XII, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRISING EXPENSES REPORTED ON PART VIII LINE 8B 63,482. 1 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 A GRANT TO A RECIPIENT IN THAT REGION 30000 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 A GRANT TO A RECIPIENT IN THAT REGION 30000 SOUTH ASIA 0 0 A GRANT TO A RECIPIENT IN THAT REGION 30000 0 0 0 0 0 0 90000 0 90000 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, RESEARCH 30000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 30000 WIRE TRANSFER 0 SOUTH ASIA RESEARCH 30000 WIRE TRANSFER 0 3 0 0 0 0 0 0 PART I, LINE 2: AAMDSIF PROVIDES RESEARCH GRANTS TO INVESTIGATORS STUDYING BONE MARROW FAILURE. THE RESEARCH MAY BE CONDUCTED IN THE U.S. OR ABROAD BUT NOT AT A FOR-PROFIT LABORATORY IN THE PRIVATE SECTOR. THE TWO-YEAR $60,000 GRANTS ARE PAID IN QUARTERLY PAYMENTS OF $7,500, FOR A TOTAL OF $30,000 PER YEAR. GRANTEES MUST SUBMIT A FIRST-YEAR PROGRESS REPORT TO DEMONSTRATE ADEQUATE PROGRESS FOR CONTINUED FUNDING. A FINAL REPORT ON THE RESEARCH PROJECT AND A FINAL FINANCIAL REPORT ON THE USE OF FUNDS IS REQUIRED FOLLOWING THE COMPLETION OF THE GRANT PERIOD. SCIENTIFIC SUMMIT 217810 210000 7810 7836 22185 MARCH FOR MARROW 127621 125441 2180 2104 25912 2 151252 145176 6076 478 4967 496683 480617 16066 8314 2104 53064 63482 -47416 1 CLEVELAND CLINIC FOUNDATION 6801 BRECKVILLE RD RK1-85 INDEPENDENCE OH 44131 340714585 501(C)(3) 30000 0 RESEARCH CITY OF HOPE 1500 E DUARTE ROAD DUARTE CA 91010 340714585 501(C)(3) 30000 0 RESEARCH THE JOHNS HOPKINS UNIVERSITY 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 521465301 501(C)(3) 30000 0 RESEARCH THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 455 BROADWAY REDWOOD CITY CA 940633126 941156365 501(C)(3) 30000 0 RESEARCH 4 0 PNH TRAVEL GRANT 7 5388 PART I, LINE 2: AS WITH ALL OF OUR TWO-YEAR RESEARCH GRANTS, PROGRESS REPORTS ARE REQUIRED TO BE SUBMITTED AFTER THE FIRST YEAR AND A FINAL REPORT IS REQUIRED AT THE CONCLUSION OF THE SECOND YEAR. THESE REPORTS ARE REVIEWED AND APPROVED BY OUR MEDICAL ADVISORY BOARD. SECOND YEAR FUNDING IS CONTINGENT UPON SUBMISSION OF THE FIRST YEAR PROGRESS REPORT AND INDICATION OF FIRST YEAR PROGRESS IN MEETING THE OBJECTIVES OF THE STUDY. X X X X 0 0 0 0 0 0 0 0 0 BRAD A WONG CEO & EXECUTIVE DIRECTOR 238193 0 40000 0 0 0 12200 0 23784 0 314177 0 0 0 AZALEA CANDELARIA SR. DIRECTOR OF DEVELOPMENT 169537 0 12000 0 0 0 0 0 8473 0 190010 0 0 0 ALICE HOUK SR. DIR. OF PATIENT & PROF'L PROGRAM 148779 0 3000 0 0 0 6149 0 14263 0 172191 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTANTS AND REVIEWED BY THE FINANCE AND AUDIT COMMITTEES. A FINAL COPY OF THE FORM 990 WAS DISTRIBUTED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C BEFORE ANY CONTRACTS FOR THE PURCHASE OF GOODS OR SERVICES ARE AWARDED, MANAGEMENT AND STAFF REVIEW THEM FOR ANY POTENTIAL, PERCEIVED AND/OR REAL CONFLICTS OF INTEREST WITH RESPECT TO BOARD MEMBERS, KEY VOLUNTEERS OR STAFF. IN THE EVENT OF CONFLICT OF INTEREST, THE MATTER IS REFERRED TO THE EXECUTIVE COMMITTEE OF THE BOARD FOR DISCUSSION AND RESOLUTION. FORM 990, PART VI, SECTION B, LINE 15A THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR'S PERFORMANCE & COMPENSATION IS REVIEWED BY THE EXECUTIVE COMMITTEE USING COMPENSATION STUDIES PUBLISHED BY ASAE, BOARD SOURCE & OTHERS FOR COMPARATIVE DATA. THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR'S SALARY IS APPROVED BY THE EXECUTIVE COMMITTEE WHICH THEN INFORMS THE BOARD. THIS ENTIRE PROCESS IS DOCUMENTED. SALARIES OF ALL STAFF ARE REVIEWED ANNUALLY BY THE CHIEF EXECUTIVE OFFICER USING COMPENSATION SURVEY DATA FOR COMPARABLE SIZE AND TYPE ORGANIZATIONS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC IN PRINT AND/OR ELECTRONIC FORM UPON REQUEST, AT NO COST. FORM 990, PART IX, LINE 11G PROFESSIONAL AND CONTRACT SERVICES: PROGRAM SERVICE EXPENSES 401,892. MANAGEMENT AND GENERAL EXPENSES 8,063. FUNDRAISING EXPENSES 6,502. TOTAL EXPENSES 416,457. FORM 990, PART XII, LINE 2C THE ORGANIZATION HAS NOT CHANGED EITHER ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR REGARDING THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT.